(Q53903012)

22 May 2018

title

Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study. (English)

1 reference

22 May 2018

0 references

1 reference

1

1 reference

22 May 2018

author name string

Cheine M

2

1 reference

22 May 2018

Tuisku K

3

1 reference

22 May 2018

Ahokas A

4

1 reference

22 May 2018

Joffe G

5

1 reference

22 May 2018

Rimón R

6

1 reference

22 May 2018

publication date

1 August 2000

1 reference

22 May 2018

Progress in Neuro-Psychopharmacology & Biological Psychiatry

published in

1 reference

22 May 2018

volume

24

1 reference

22 May 2018

issue

6

1 reference

22 May 2018

page(s)

911-922

1 reference

22 May 2018

Clozapine-induced agranulocytosis. Incidence and risk factors in the United States

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900118-4

7 January 2021

The Social Functioning Scale. The development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900118-4

7 January 2021

Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900118-4

7 January 2021

Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900118-4

7 January 2021

A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900118-4

7 January 2021

Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900118-4

7 January 2021

Long-term effect on outcome of clozapine in chronic therapy-resistant schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900118-4

7 January 2021

Duration of a clozapine trial in neuroleptic-resistant schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900118-4

7 January 2021

What are pragmatic trials?

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900118-4

7 January 2021

Meta-analyses of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900118-4

7 January 2021

Influence of methodology on outcomes of randomised clozapine trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900118-4

7 January 2021

Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2800%2900118-4

7 January 2021

10.1016/S0278-5846(00)00118-4

Identifiers

DOI

1 reference

22 May 2018

1 reference

22 May 2018